Product Description
Mechanisms of Action: 3CLpro Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cocrystal Pharma
Company Location: BOTHELL WA 98011
Company CEO: Sam Lee
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: COVID-19|Severe Acute Respiratory Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CDI-988-P1-001 | P1 |
Recruiting |
Severe Acute Respiratory Syndrome|COVID-19 |
2025-05-01 |